@prefix dcterms: <http://purl.org/dc/terms/> .
@prefix ns1: <http://www.w3.org/ns/prov#> .
@prefix this: <http://purl.org/np/RARzgTwmS5JyfdRS-tdwF1Ms8TBqwfXnkVII4bB6cmAH8> .
@prefix sub: <http://purl.org/np/RARzgTwmS5JyfdRS-tdwF1Ms8TBqwfXnkVII4bB6cmAH8#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix bl: <https://w3id.org/biolink/vocab/> .
@prefix npx: <http://purl.org/nanopub/x/> .
sub:Head {
  this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:pubinfo ;
    a np:Nanopublication .
}
sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_594> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_594> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB00472> ;
    a rdf:Statement ;
    rdfs:label "prozac is indicated for the treatment of major depressive disorder adult see clinical trials a major depressive episode dsm iv implies a prominent and relatively persistent nearly every day for at least 2 weeks depressed or dysphoric mood that usually interferes with daily functioning and includes at least 5 of the following 9 symptoms depressed mood loss of interest in usual activities significant change in weight and or appetite insomnia or hypersomnia psychomotor agitation or retardation increased fatigue feelings of guilt or worthlessness slowed thinking or impaired concentration a suicide attempt or suicidal ideation the effects of prozac in hospitalized depressed patients have not been adequately studied the efficacy of prozac 2 mg once daily in maintaining a response in major depressive disorder for up to 38 weeks following 12 weeks of open label acute treatment 5 weeks total was demonstrated in a placebo controlled trial the efficacy of prozac weekly once weekly in maintaining a response in major depressive disorder has been demonstrated in a placebo controlled trial for up to 25 weeks following open label acute treatment of 13 weeks with prozac 2 mg daily for a total treatment of 38 weeks however it is unknown whether or not prozac weekly given on a once weekly basis provides the same level of protection from relapse as that provided by prozac 2 mg daily see clinical trials pediatric children and adolescents see clinical trials the usefulness of the drug in adult and pediatric patients receiving fluoxetine for extended periods should be reevaluated periodically adult the efficacy of prozac was established in 13 week trials with obsessive compulsive outpatients whose diagnoses corresponded most closely to the dsm iii r category of ocd see clinical trials ocd is characterized by recurrent and persistent ideas thoughts impulses or images obsessions that are ego dystonic and or repetitive purposeful and intentional behaviors compulsions that are recognized by the person as excessive or unreasonable the effectiveness of prozac in long term use i e for more than 13 weeks has not been systematically evaluated in placebo controlled trials therefore the physician who elects to use prozac for extended periods should periodically reevaluate the long term usefulness of the drug for the individual patient see dosage and administration pediatric children and adolescents see clinical trials prozac is indicated for the treatment of binge eating and vomiting behaviors in patients with moderate to severe bulimia nervosa the efficacy of prozac was established in 8 to 16 week trials for adult outpatients with moderate to severe bulimia nervosa i e at least 3 bulimic episodes per week for 6 months see clinical trials the efficacy of prozac 6 mg day in maintaining a response in patients with bulimia who responded during an 8 week acute treatment phase while taking prozac 6 mg day and were then observed for relapse during a period of up to 52 weeks was demonstrated in a placebo controlled trial see clinical trials see dosage and administration prozac is indicated for the treatment of panic disorder with or without agoraphobia as defined in dsm iv panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks worry about the implications or consequences of the attacks and or a significant change in behavior related to the attacks the efficacy of prozac was established in two 12 week clinical trials in patients whose diagnoses corresponded to the dsm iv category of panic disorder see clinical trials panic disorder dsm iv is characterized by recurrent unexpected panic attacks i e a discrete period of intense fear or discomfort in which 4 or more of the following symptoms develop abruptly and reach a peak within 1 minutes 1 palpitations pounding heart or accelerated heart rate 2 sweating 3 trembling or shaking 4 sensations of shortness of breath or smothering 5 feeling of choking 6 chest pain or discomfort 7 nausea or abdominal distress 8 feeling dizzy unsteady lightheaded or faint 9 fear of losing control 1 fear of dying 11 paresthesias numbness or tingling sensations 12 chills or hot flashes the effectiveness of prozac in long term use i e for more than 12 weeks has not been established in placebo controlled trials therefore the physician who elects to use prozac for extended periods should periodically reevaluate the long term usefulness of the drug for the individual patient see dosage and administration" ;
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation schema:TreatmentIndication .
  <https://identifiers.org/drugbank:DB00472> bl:category bl:Drug .
}
sub:provenance {
  sub:assertion ns1:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA" ;
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" ;
    npx:hasSignature "Cna8tlEKb1WOsMWyQ1nLko6b6EM+MrjlTkmMzVv0GDTZjYlhcxv/mtKk14O1fl5HuaBwXZJFoK6Q0G1qTRo7KJ2PGkE4LRyk3bRPRnkZwI6ZT7JV2HGEZbDw1maNCTp8vtXY2rDAlvHvurrxqhyZN6qytRHhTF7wjexqQa2Dwu0=" ;
    npx:hasSignatureTarget this: .
  this: dcterms:created "2021-06-28T08:18:11.560+02:00"^^xsd:dateTime ;
    dcterms:creator orcid:0000-0002-1468-3557 ;
    nt:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM> ;
    nt:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM> ;
    nt:wasCreatedFromTemplate <http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs> .
}